These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36989810)

  • 1. Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2023 Apr; 252():115295. PubMed ID: 36989810
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
    Tong B; Spradlin JN; Novaes LFT; Zhang E; Hu X; Moeller M; Brittain SM; McGregor LM; McKenna JM; Tallarico JA; Schirle M; Maimone TJ; Nomura DK
    ACS Chem Biol; 2020 Jul; 15(7):1788-1794. PubMed ID: 32568522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma" [Eur. J. Med. Chem. 140 (2017) 84-91].
    Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
    Eur J Med Chem; 2020 Sep; 202():112633. PubMed ID: 32688164
    [No Abstract]   [Full Text] [Related]  

  • 5. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
    Cieślak M; Słowianek M
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation.
    Jiang L; Wang Y; Li Q; Tu Z; Zhu S; Tu S; Zhang Z; Ding K; Lu X
    Acta Pharm Sin B; 2021 May; 11(5):1315-1328. PubMed ID: 34094836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum to "Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia" [Eur. J. Med. Chem. 221 (2021) 113522].
    Ge H; Zhang W; Yuan K; Xue H; Cheng H; Chen W; Xie Y; Zhang J; Xu X; Yang P
    Eur J Med Chem; 2022 Jan; 228():114041. PubMed ID: 34902733
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
    Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
    Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
    [No Abstract]   [Full Text] [Related]  

  • 11. Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
    Yang Y; Gao H; Sun X; Sun Y; Qiu Y; Weng Q; Rao Y
    J Med Chem; 2020 Aug; 63(15):8567-8583. PubMed ID: 32657579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
    Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
    Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors" [Eur. J. Med. Chem. 180 (2019) 171e190].
    Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
    Eur J Med Chem; 2020 Jan; 186():111899. PubMed ID: 31787358
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
    Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
    J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum to "New desulfured troglitazone derivatives: Improved synthesis and biological evaluation" [Eur. J. Med. Chem. 187 (2020) 111939].
    Dupommier D; Muller C; Comoy C; Mazerbourg S; Bordessa A; Piquard E; Pawlak M; Piquard F; Martin H; De Fays E; Grandemange S; Flament S; Boisbrun M
    Eur J Med Chem; 2020 Dec; 208():112834. PubMed ID: 32966897
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer" [Bioorgan. Chem. 119 (2022) 105505].
    Lier S; Sellmer A; Orben F; Heinzlmeir S; Krauß L; Schneeweis C; Hassan Z; Schneider C; Schäfer A; Pongratz H; Engleitner T; Öllinger R; Kuisl A; Bassermann F; Schlag C; Kong B; Dove S; Kuster B; Rad R; Reichert M; Wirth M; Saur D; Mahboobi S; Schneider G
    Bioorg Chem; 2024 May; 146():107248. PubMed ID: 38458892
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer's disease" [Eur. J. Med. Chem. 265 (2024) 116071].
    Liu Y; Ma C; Li Y; Li M; Cui T; Zhao X; Li Z; Jia H; Wang H; Xiu X; Hu D; Zhang R; Wang N; Liu P; Yang H; Cheng M
    Eur J Med Chem; 2024 Mar; 267():116169. PubMed ID: 38290915
    [No Abstract]   [Full Text] [Related]  

  • 18. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
    Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
    Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
    Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
    Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents" [Eur. J. Med. Chem. 162 (162) (2019) 203-211].
    Su L; Li J; Zhou Z; Huang D; Zhang Y; Pei H; Guo W; Wu H; Wang X; Liu M; Yang CG; Chen Y
    Eur J Med Chem; 2019 Apr; 168():385. PubMed ID: 30826513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.